The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Open accessAbstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known. METHODS: We conducted a 72-week, double-blind phase 2 trial involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3. Patients were randomly assigned, in a 3:3:3:1:1:1 ratio, to receive once-daily subcutaneous semaglutide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo. The primary end point was resolution of NASH with no worsening of fibrosis. The confirmatory secondary end point was an improvement of at least one fibrosis stage with no worsening of NASH. The analyses of these end points were performed only in patients with stage F2 or F3 fibrosis; other analyses were performed in all the patients. RESULTS: In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to receive semaglutide at a dose of 0.1 mg (80 patients), 0.2 mg (78 patients), or 0.4 mg (82 patients) or to receive placebo (80 patients). The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo). An improvement in fibrosis stage occurred in 43% of the patients in the 0.4-mg group and in 33% of the patients in the placebo group (P = 0.48). The mean percent weight loss was 13% in the 0.4-mg group and 1% in the placebo group. The incidence of nausea, constipation, and vomiting was higher in the 0.4-mg group than in the placebo group (nausea, 42% vs. 11%; constipation, 22% vs. 12%; and vomiting, 15% vs. 2%). Malignant neoplasms were reported in 3 patients who received semaglutide (1%) and in no patients who received placebo. Overall, neoplasms (benign, malignant, or unspecified) were reported in 15% of the patients in the semaglutide groups and in 8% in the placebo group; no pattern of occurrence in specific organs was observed. CONCLUSIONS: This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placebo. However, the trial did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT02970942.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality.5,7–9,11,30”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, a 2020 clinical trial involving patients with nonalcoholic steatohepatitis (NASH) revealed a 15% incidence of tumors (benign, malignant, or unspecified) (35/239) among those administered semaglutide, compared to 8% (6/80) in the control group [108].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrosis improvement (43% vs. 33%) did not reach significance, likely due to study duration.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a 72-week phase 2 RCT of 1197 participants with biopsy-confirmed MASH and F2–F3 fibrosis, semaglutide 0.4 mg/day achieved a significant MASH resolution in 59% vs. 17% with placebo [54].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [54]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In MASLD and MASH, semaglutide induces histological improvement, including MASH resolution and fibrosis regression, with > 60% of patients achieving resolution in F2–F3 stages.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both treatments were accompanied by a weight loss of 5.5 % and 12.5 % as well as a HbA1c reduction of 0.5 % and 1.2 %, respectively.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both treatments were accompanied by a weight loss of 5.5 % and 12.5 % as well as a HbA1c reduction of 0.5 % and 1.2 %, respectively.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest available trial on semaglutide in MASH ( vs . placebo over an 18-month treatment period) demonstrated resolution of steatohepatitis but no fi brosis improvement.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [401]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Weight loss achieved with use of GLP-1 RAs and the GIP/GLP-1 RA is also beneficial for obstructive sleep apnea (132), knee osteoarthritis (133), and metabolic dysfunction–associated steatohepatitis (MASH) (134–136).”
From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“semaglutide showed a trend for improvements in fibrosis stage, 82”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [82]
The cited source says what the claim attributes to it.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
The cited source says what the claim attributes to it.
In the citing paper
“Studies conducted with semaglutide showed relevant weight losses, accompanied by consistent metabolic benefits, while investigations in patients with steatohepatitis demonstrated a significant increase in the rates of resolution of liver disease”
From RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW (2026) · cites this paper as NEWSOME et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“The glucagon‐like peptide‐1 receptor agonist semaglutide has shown a significantly higher percentage of patients with NASH resolution (and no worsening of fibrosis) compared to placebo in a 72‐week, double‐blind phase 2 trial involving 320 patients with biopsy‐confirmed NASH and fibrosis stage 1–340.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“Improvement in fibrosis stage was seen in 43% of NASH patients and 33% of placebo patients, but this difference was not statistically significant [40].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“around 38% of patients in the study had no (!) diabetes mellitus, however all had at least a BMI >25.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“However, no overall improvement in fibrosis grade was detected, despite lower reported rates of fibrosis progression for liraglutide [108,109].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“MASH resolution was mainly driven by improvements in steatosis and ballooning for liraglutide [108], whereas semaglutide also reduced inflammation [109].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Two RCTs with liraglutide and semaglutide in mixed collectives of people with and without type 2 diabetes provided evidence for higher rates of histological MASH resolution without worsening of fibrosis compared to placebo (Table 1).”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [109]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In 3 studies of 56-week duration involving persons with obesity and dyslipidemia or hypertension, weight loss ranged from 6.2% to 8.0% with 3 mg liraglutide vs 0.2% to 2.9% with placebo.754–756”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [756]
Experimental — accuracy not yet measuredIn the citing paper
“Growing evidence supports the positive impact of GLP-1 RAs in reducing hepatic cytolysis enzymes [56,61,69,70,71,72,73,74,75,76,77,78,79,80,81] (Table 2).”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“If semaglutide at a dosage of 0.4 mg/day leads to resolution of steatohepatitis in 59% of cases, no significant difference emerged in the improvement of fibrosis compared to placebo.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“In this regard, GLP-1 RAs have been proven to significantly improve hepatic steatosis.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“Furthermore, an improvement in NAS was observed in 83% of patients treated with semaglutide 0.4 mg/day, 80% of those treated with 0.2 mg/day, 71% of those treated with 0.1 mg/day and only 44% of those treated with placebo.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“After 72 weeks, treatment with semaglutide at a dose of 0.4 mg/day resulted in the histological resolution of NASH without progression of fibrosis in 59% of patients, compared with 17% in the placebo group.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“However, the treatment was shown to be effective in reducing the progression of fibrosis (5% vs. 19% of the placebo group), in accordance with what previously demonstrated [56].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [61]
In the citing paper
“As GLP-1 agonism has promoted NASH resolution in a phase II trial,48”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [48]
In the citing paper
“Among adults with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3, semaglutide 0.4 mg s.c.versus placebo daily for 72 weeks improved steatohepatitis resolution with no worsening of fibrosis, but there was no between-group difference in improvement of fibrosis stage.115”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [115]
In the citing paper
“In people with MASH (with and without diabetes), semaglutide 0.4 mg once daily for 72 weeks demonstrated that 59% of them could achieve MASH resolution with no worsening of fibrosis compared to placebo, however there was not improvement in fibrosis stage [57].”
In the citing paper
“Nevertheless, GLP-1 RAs such as liraglutide 1.8 mg once daily and semaglutide 2.4 mg once weekly have demonstrated their benefits in MASH resolution compared to placebo, without however improvement in fibrosis [57,88].”
In the citing paper
“Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD).”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [16]
In the citing paper
“More recently, semaglutide, a more potent GLP1-RA, has achieved resolution of MASH in up to 59% of people and this was associated with a 13% reduction in weight.16”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [16]
In the citing paper
“However, the impact on liver fibrosis is less clear.16,17”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [16]
In the citing paper
“There is now an established body of evidence demonstrating the beneficial impact of GLP-1RA in people with MASLD to decrease hepatic steatosis and resolve MASH15,16,30,31”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [16]
In the citing paper
“of GLP-1 receptor agonists has recently been demonstrated by phase 2 studies with liraglutide194 and semaglutide,195”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Neoplasms‡ 10 (12) 11 (14) 14 (17) 6 (8)”
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Self-citationSheka, A. C., Adeyi, O. A., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020) · JAMA · doi:10.1001/jama.2020.2298 · Cited by 1,432
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Cited by
Sorted by citations
Items 801–900 of 1,005
Kloock, S., Haerting, N., Herzog, G., Oertel, M., Geiger, N., Geier, A., Sequeira, V., Nickel, A. G., Kohlhaas, M., Faßnacht, M., et al. (2024) · Nutrients · doi:10.3390/nu16060904 · Cited by 15
Amoroso, M., Augustín, S., Moosmang, S., & Gashaw, I. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02448-2 · Cited by 15
Sawamura, T., Mizoguchi, R., Ohmori, A., Kometani, M., Yoneda, T., & Karashima, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01472-w · Cited by 17
Liu, Y., Fan, Y., Liu, J., Liu, X., Li, X., & Hu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1499602 · Cited by 15
A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 15
Self-citationJatana, S., Krys, D., Verhoeff, K. K., Kung, J. Y. C., Jogiat, U., Montaño‐Loza, A. J., Shapiro, A. M. J., Dajani, K. Z., Anderson, B. L., & Bigam, D. L. (2024) · Transplantation · doi:10.1097/tp.0000000000005276 · Cited by 15
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology
Zhou, X., Targher, G., Byrne, C. D., Shapiro, M. D., Chen, L.-L., & Zheng, M. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000106 · Cited by 15
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
Reytor-González, C., Annunziata, G., Campuzano-Donoso, M., Morales-López, T., Basantes-Tituaña, C., Fascì-Spurio, F., Verde, L., Muscogiuri, G., Barrea, L., Frías-Toral, E., et al. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04314-8 · Cited by 15
Ratziu, V., Surabattula, R., Bugianesi, E., Schattenberg, J. M., Myneni, S. R., Rosso, C., Armandi, A., Pais, R., Kara, L., Charlotte, F., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335598 · Cited by 15
Self-citationGao, F., Zheng, K. I., Chen, S., Lee, D. H., Wu, X.-X., Wang, X.-D., Targher, G., Byrne, C. D., Chen, Y.-P., Kim, W. K., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000321 · Cited by 15
Ampuero, J., Gallego‐Durán, R., Maya‐Miles, D., Montero, R., Gato, S., Rojas, Á., Gil‐Gómez, A., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01860-0 · Cited by 15
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
Self-citationAhmed, N. R., Kulkarni, V. V., Pokhrel, S., Akram, H., Abdelgadir, A., Chatterjee, A., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.24829 · Cited by 15
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Self-citationZou, Y., Zhao, L., Zhang, J., Wang, Y., Wu, Y., Ren, H., Wang, T., Zhao, Y., Xu, H., Li, L., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01978-w · Cited by 15
O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease
Zhou, Y., Li, Z., Xu, M., Zhang, D., Ling, J., Yu, P., & Shen, Y. (2022) · Cells · doi:10.3390/cells11223637 · Cited by 15
Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110191 · Cited by 15
Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis
Xiong, F., Zhou, Q., Huang, X., Cao, P., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055793 · Cited by 15
Li, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Self-citationNutrition in Liver Disease – A Review
Hepburn, C., & Roenn, N. V. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00887-4 · Cited by 15
Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease
Li, J., Delamarre, A., Wong, V. W., & de Lédinghen, V. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12491 · Cited by 15
Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes
Kuriyama, T., Ishibashi, C., Kozawa, J., Baden, M. Y., Horii, T., Niki, A., Ozawa, H., Hosokawa, Y., Fujita, Y., Sadahiro, K., et al. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.12.005 · Cited by 15
Ono, H., Atsukawa, M., Tsubota, A., Arai, T., Suzuki, K. M., Higashi, T., Kitamura, M., Shioda, K., Kawano, T., Yoshida, Y., et al. (2024) · JGH Open · doi:10.1002/jgh3.13057 · Cited by 15
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 15
Ordóñez-Vázquez, A. L., Gall, S. M.-B., Pal, S. C., & Méndez‐Sánchez, N. (2022) · Medical Science Monitor · doi:10.12659/msm.938365 · Cited by 15
Hansen, J. K., Israelsen, M. E., Nishijima, S., Stinson, S. E., Andersen, P., Johansen, S., Hansen, C. D., Brol, M. J., Klein, S., Schierwagen, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60755-9 · Cited by 14
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 14
Pi, S., Zhang, S., Zhang, J., Guo, Y., Li, Y., Deng, J., & Du, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1626352 · Cited by 14
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Basha, A., May, S. C., Anderson, R. M., Samala, N. R., & Mirmira, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129996 · Cited by 14
Weight loss and metabolic benefits of bariatric surgery in China : A multicenter study
Feng, W., Zhu, Z., Li, X., Zhou, Z., Qu, S., Sun, X., & Zhu, D. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13430 · Cited by 14
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 14
Atthota, S., Joyal, K., Cote, M., Scalzo, R., Singh, R., Consul, N., Kilcoyne, A., Bethea, E. D., & Dageforde, L. A. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1223169 · Cited by 14
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 14
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Xie, Y., Jin, Y., Wen, J., Li, G., Huai, X., Duan, Y., Ni, F., Fu, J., Li, M., Li, L., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116908 · Cited by 14
Liu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 14
Wong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Rautou, P., Chotkoe, S., Biquard, L., Wettstein, G., van der Graaff, D., Liu, Y., Man, J. D., Casteleyn, C. R., Thys, S., Vos, W. H. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101366 · Cited by 14
Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. D. (2025) · Diabetology · doi:10.3390/diabetology6040023 · Cited by 14
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Obesity and Nonalcoholic Fatty Liver Disease
Chaney, A. J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.009 · Cited by 14
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 14
Kovalic, A. J. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.01.011 · Cited by 14
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Suri, J. S., Borja, S., & Lim, J. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i35.5129 · Cited by 14
Barbieri, E., Santoro, N., & Umano, G. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1062341 · Cited by 14
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 15
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 14
Domingues, I., Yagoubi, H., Zhang, W., Marotti, V., Kambale, E. K., Vints, K., Śliwińska, M. A., Leclercq, I. A., & Beloqui, A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01576-z · Cited by 14
Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus
Labenz, C., Kostev, K., Alqahtani, S. A., Galle, P. R., & Schattenberg, J. M. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1378-4679 · Cited by 14
Liu, L., Xia, Y., Wang, B., & Zhang, Y. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70084 · Cited by 13
Decoding the CHI3L1/IL-13Rα2 signaling nexus in MASH-fibrosis pathogenesis
Zheng, Q., Cao, Y., Jiang, X., Wang, X., Wang, X., He, Y., Ma, W., Wu, H., Jiang, Y., WANG, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz3223 · Cited by 13
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
Meyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
Self-citationMetformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome
Riemann, A., Blaschke, M., Jauho-Ghadimi, A., Siggelkow, H., & Gollisch, K. S. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154294 · Cited by 13
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 13
Tsiampali, C., Vachliotis, I. D., Goulas, A., & Pοlyzos, S. A. (2024) · HORMONES · doi:10.1007/s42000-024-00541-2 · Cited by 13
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 13
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 13
Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
Gao, X., Zhu, C., Zhu, W. M., & Wang, L. (2024) · Biomedical Reports · doi:10.3892/br.2024.1904 · Cited by 13
Ren, R., Pei, Y., Kong, L., & Shi, Y. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108932 · Cited by 13
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Potter, K. J., Phinney, J., Kulai, T. B., & Munro, V. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae057 · Cited by 13
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025) · Biomolecules · doi:10.3390/biom15091284 · Cited by 13
Martínez‐Urbistondo, D., San-Cristóbal, R., Villares, P., Martínez‐González, M. Á., Babió, N., Corella, D., García, J. L. D. V., Ordovás, J. M., Alonso‐Gómez, Á. M., Wärnberǵ, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868795 · Cited by 13
Co-agonist therapeutics come of age for obesity
Tan, T. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00788-y · Cited by 13
Update on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 13
Eeda, V., Patil, N. Y., Joshi, A. D., & Awasthi, V. (2023) · Hepatology Research · doi:10.1111/hepr.14008 · Cited by 13
Katsuyama, H., Hakoshima, M., Kaji, E., Mino, M., Kakazu, E., Iida, S., Adachi, H., Kanto, T., & Yanai, H. (2024) · Biomedicines · doi:10.3390/biomedicines12051001 · Cited by 13
Morieri, M. L., Targher, G., Lapolla, A., D'Ambrosio, M., Tadiotto, F., Rigato, M., Frison, V., Paccagnella, A., Simioni, N., Avogaro, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.049 · Cited by 13
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Mantovani, A., & Targher, G. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-2021-13 · Cited by 13
Semaglutide or Placebo for Nonalcoholic Steatohepatitis
Newsome, P. N., Sejling, A.-S., & Sanyal, A. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2106921 · Cited by 13
Self-citationNew horizons in the diagnosis and management of patients with MASLD
van Erpecum, K. J., & Dalekos, G. Ν. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.038 · Cited by 13
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Nomoto, H., Takahashi, Y., Takano, Y., Yokoyama, H., Tsuchida, K., Nagai, S., Miya, A., Kameda, H., Cho, K. Y., Nakamura, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082163 · Cited by 12
Fan, Y., Xia, M., Yan, H., Li, X., & Chang, X. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15359 · Cited by 12
Butcko, A. J., Putman, A. K., & Mottillo, E. P. (2024) · Antioxidants · doi:10.3390/antiox13010087 · Cited by 12
Hénin, G., Loumaye, A., Deldicque, L., Leclercq, I. A., & Lanthier, N. (2024) · Liver International · doi:10.1111/liv.15938 · Cited by 12
McGlone, E. R., Hope, D. C. D., Davies, I., Dore, M. H., Goldin, R. D., Jones, B. J., Liu, Z., Li, J. V., Vorkas, P. A., Khoo, B. C. E., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116888 · Cited by 12
Pramanik, S., Pal, P., & Ray, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i2.91319 · Cited by 12
Júnior, W. S. D. S., Sposito, A. C., & Godoy‐Matos, A. F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.034 · Cited by 12
Stratina, E., Stanciu, C., Năstasă, R., Zenovia, S., Stafie, R., Rotaru, A., Cuciureanu, T., Muzica, C. M., Sfarti, C. V., Gîrleanu, I., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14141475 · Cited by 12
Zhang, S., Cui, Z., Zhang, H., Wang, P., Wang, F., & Zhang, J. (2024) · Nutrients · doi:10.3390/nu16142232 · Cited by 12
Hu, Q., Zhang, L., Tao, Y., Xie, S., Wang, A., Luo, C., Yang, R., Shen, Z., He, B. H., Fang, Y., et al. (2024) · Pharmacology · doi:10.1159/000540654 · Cited by 12
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Liang, M., Xiao, X., Chen, M., Guo, Y., Han, W., Min, Y., Jiang, X., & Yu, W. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119030 · Cited by 12
Fukunaga, K., Morishita, A., Imachi, H., Oura, K., Sato, S., Kobayashi, T., Saheki, T., Yoshimura, T., Komori, K., Nakahara, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16157 · Cited by 12
Opportunistic Screening of Chronic Liver Disease with Deep-Learning–Enhanced Echocardiography
Sahashi, Y., Vukadinovic, M., Amrollahi, F., Trivedi, H. D., Rhee, J., Chen, J. H., Cheng, S. C., Ouyang, D., & Kwan, A. C. (2025) · NEJM AI · doi:10.1056/aioa2400948 · Cited by 12
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 12
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 12
Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
Kuo, C.-C., Li, C., Chuang, M., Huang, P., Kuo, H., & Lai, C. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000747 · Cited by 12
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 12
Metadata
- Authors
- Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-25
- Volume
- 384
- Issue
- 12
- Pages
- 1113-1124
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3102426258
- Cited by
- 2,039
- References
- 28
- Citations by year
- 2026: 352 · 2025: 458 · 2024: 417 · 2023: 334 · 2022: 264 · 2021: 205
- FWCI
- 145.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, semaglutide, GLP-1 receptor agonists, liver fibrosis, NASH resolution, weight loss, adverse events, nausea, constipation, vomiting, dose comparison, obesity-related liver disease, drug safety and efficacy, GIP/GLP-1 receptor agonist
- MeSH terms
- Semaglutide, Adolescent, Adult, Aged, Amylases, Biopsy, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Lipase, Liver, Liver Cirrhosis, Male, Middle Aged, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
